Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis (FSGS) FSGS is a term that describes a pattern of scarring in the kidneys. This scarring can be seen on a biopsy in patients with increased levels … Read more
Showing results for isu fsgs
Focal Segmental Glomerulosclerosis (FSGS) FSGS is a term that describes a pattern of scarring in the kidneys. This scarring can be seen on a biopsy in patients with increased levels … Read more
We recently sat down with Dr. Ogo Egbuna, Vertex Pharmaceutical’s clinical development lead for their clinical trial in APOL1-mediated focal segmental glomerulosclerosis (FSGS) to learn a bit more about their … Read more
Externally led patient-focused drug development (EL-PFDD) meetings bring together patients and care partners, US Food and Drug Administration (FDA) representatives, pharmaceutical companies, and doctors who are experts in the particular … Read more
Contact both your Senators and ask that they sign on to Senator Debbie Stabenow’s (D-MI) letter supporting the inclusion of “focal segmental glomerulosclerosis (FSGS)” as condition eligible for study through … Read more
At the age of 20 years old, Bala Krishnalal’s life was forever changed by the results of a kidney biopsy. In 2014, after suffering from recurring fevers for two years, Bala Krishnalal … Read more
Have you or your loved one been diagnosed with FSGS? We have resources for you. The rates of severe kidney disease are high in individuals who are African American, Hispanic … Read more
A new educational resource is available for FSGS patients worldwide. We are proud to collaborate with WebMD/Medscape to make focal segmental glomerulosclerosis (FSGS) available as a program on the WebMD … Read more
Remember When… Back in January, FSGS was officially added to the list of conditions eligible for research funding through the Department of Defense’s 2015 Peer Reviewed Medical Research Program (PRMRP). … Read more
On December 9, 2023, researchers, doctors, regulators, and patients from across the globe met in Washington, D.C. at the Proteinuria and GFR as Clinical Trial Endpoints in Focal Segmental Glomerulosclerosis … Read more
Goldfinch Bio is a biotechnology company based in Cambridge, MA which focuses on delivering disease-modifying precision medicines that bring hope and renewed quality of life to people living with kidney … Read more
Potential FSGS Treatment Option To Be Tested In Phase 3 Clinical Trial Early in March, Retrophin, Inc. announced plans to launch a phase 3 clinical trial to evaluate a potential … Read more